Neurodegenerative drug development is advancing rapidly across Alzheimer’s, ALS and Parkinson’s disease as well as other related central nervous system (CNS) indications. For biotech sponsors, the challenge is translating biomarkers, digital measures, adaptive designs and other innovations into credible evidence, feasible trials and development plans that can withstand regulatory, investor and site-level scrutiny.
These early decisions about endpoints, patient identification and site readiness can determine whether a program gains momentum or loses time.
Regulatory Strategy Must Start Before the Protocol Is Finalized
One of the defining challenges in CNS therapy development is that each indication sits in a different evidentiary environment and has distinct regulatory standards. Alzheimer’s disease has moved further toward biologically defined populations and biomarker-enabled development but requires amyloid-related imaging abnormalities (ARIA) monitoring and APOE4-informed risk assessment. While ALS remains anchored largely in clinical endpoints with biomarkers playing a supportive role in select contexts. Tofersen, was the first genetically targeted therapy approved for SOD1-ALS and established the biomarker-surrogate precedent. While Parkinson’s biological and digital measures have progressed, research lacks a validated surrogate endpoint and remains anchored in clinical outcomes.
Sponsors should therefore assess the appropriate biomarker, endpoint and pathway by disease and not apply a universal CNS template. Early regulator engagement can clarify which measures are actionable or exploratory, align evidence with the intended claim and prevent costly protocol changes.
Operational Feasibility Is a Strategic Imperative
Scientific ambition in CNS trials often collides with operational reality. Long study durations, complex eligibility criteria, specialized assessments, caregiver involvement and high screening burden can all affect recruitment, retention, timelines and data quality. As trials move into earlier-stage or asymptomatic populations, those pressures intensify. Potential participants may be harder to identify, less connected to specialty care and more likely to require additional education and support before enrolling.
Clinical operations are the strategic lever, not simply an execution function. Protocols must be designed with the realities of sites, patients and caregivers in mind.
Remote cognitive testing, speech analytics and wearable sensors are now being evaluated as digital biomarkers, offering new ways to track cognitive and functional changes over time. Screening pathways should be practical and scalable and vendor strategies should align with the needs of the study, whether that involves central imaging, specialized labs, eCOA partners, rater training or remote support models. Site feasibility should also account for workflow demands such as imaging capacity, safety monitoring, disclosure processes and study participant counseling.
In Alzheimer’s disease, for example, diagnostic and blood-based biomarkers have changed how we approach early detection. While these advances may help improve patient identification and reduce unnecessary screening burden, they also require careful planning around testing logistics, patient communication and confirmatory evidence to be successful. The operational question is not whether a tool solves a defined problem and can be implemented reliably across the study.
Responsible Innovation Requires Discipline
While innovation in neurodegenerative therapy development is essential, it must also be purposeful. Regulators, sites, patients and investors need confidence that these new approaches that are being used to strengthen evidence generation, don’t add unnecessary complexity. For this, sponsors must define the context of use for each tool or measure, clarify how it supports decision-making and build a development plan that balances scientific opportunity with practical feasibility.
Collaboration is also becoming increasingly important. Data sharing, natural history studies, registries and patient networks can help reduce uncertainty, strengthen trial readiness and improve the interpretability of results.
Turning Complexity Into Development Confidence
Advancing neurodegenerative therapies requires an integrated approach that connects regulatory strategy, clinical operations, therapeutic expertise and patient-centered execution.
Successful programs must generate evidence regulators can evaluate, sites can deliver and patients and caregivers can sustain.
As the neurogenerative landscape evolves, progress will depend on trials designed with clarity, discipline and real-world execution in mind, helping promising therapies move responsibly toward the patients and families who need them.
Planning your next CNS trial? Let’s discuss how to turn scientific ambition into an actionable development plan.